[1] N.M. Appel, J.F. Contrera, E.B. De Souza, Fenfluramine selectively [21]
and differentially decreases the density of serotonergic nerve
terminals in rat brain: evidence from immunocytochemical studies,
J. Pharmacol. Exp. Ther. 249 (1989) 928–943. [22]
[2] A. Balcioglu, R.J. Wurtman, Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum:
In vivo microdialysis study in conscious animals, Brain Res. 813
(1998) 67–72.
[3] M.C. Boadle-Biber, Regulation of serotonin synthesis, Prog. Bio- [23]
phys. Mol. Biol. 60 (1993) 1–15.
[4] S. Caccia, M. Ballabio, G. Guiso, M. Rocchetti, S. Garattini, Species
differences in the kinetics and metabolism of fenfluramine isomers,
Arch. Int. Pharmacodyn. 258 (1982) 15–28. [24]
[5] S. Caccia, S. Sarati, M. Anelli, S. Garattini, Effect of escalating
doses of D-fenfluramine on the content of indoles in brain, Neuropharmacology 31 (1992) 875–879.
[6] A. Carlsson, J.N. Davis, W. Kehr, M. Lindqvist, C.V. Atack, [25]
Simultaneous measurement of tyrosine and tryptophan hydroxylase
activities in brain in vivo using an inhibitor of the aromatic amino
acid decarboxylase, Naunyn Schmiedebergs Arch. Pharmacol. 275
(1972) 153–168. [26]
[7] J. Carlton, N. Rowland, Anorexia and brain serotonin: development
of tolerance to the effects of fenfluramine and quipazine in rats with
serotonin-depleting lesions, Pharmacol. Biochem. Behav. 20 (1984) [27]
739–745.
[8] P.J. Currie, N. Saxena, A.Y. Tu, 5-HT(2A / 2C) receptor antagonists
in the paraventricular nucleus attenuate the action of DOI on [28]
NPY-stimulated eating, Neuroreport 10 (1999) 3033–3036.
[9] G. Curzon, E.L. Gibson, A.O. Oluyomi, Appetite suppression by
commonly used drugs depends on 5-HT receptors but not on 5-HT
availability, Trends Pharmacol. Sci. 18 (1997) 21–25. [29]
R. Davis, P. Faulds, Dexfenfluramine. An updated review of its
therapeutic use in the management of obesity, Drugs 52 (1996)
696–724.
